Projects overview

Sort by


Toggle all information

ABD | A bioengineered, naturally-derived, sustainable biocide for breaking down organic biofilms formed by drug-resistant bacteria.

01-12-2016

-

30-04-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

METAdiag | METAdiag: Diagnose to Cure

01-02-2017

-

31-05-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

DeCISIoN | Drug CandIdates ScreenINg

01-07-2016

-

31-12-2018

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

OLDIAS2 | On-line Dialysis Sensor Phase2

01-08-2017

-

31-10-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

PDClungSME1 | A therapeutic vaccine candidate for lung cancer based on an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line)

01-08-2016

-

28-02-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

HbMP-700 | The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.

01-01-2017

-

30-04-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

OZONELASER | Cost and time-effective universal medical device for treatment of onychomycosis by combining several technologies

01-05-2016

-

31-10-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

OPTIMIsE | Commercial feasibility of the Novio-PlainGel: a novel synthetic, reversible thermosensitive, biomimetic hydrogel for organoid-based precision medicine

01-06-2016

-

30-09-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

CG-100 | A next generation medical device that enhances patient care and treatment following colorectal surgery

01-03-2017

-

30-06-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

FGFSTAB | Industrial Production of Stable Fibroblast Growth Factors for Regenerative Medicine and Related Research Areas

01-03-2017

-

28-02-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

TREGS4DM1 | Commercialization of TREG cells sorting and proliferation in vitro for the production of vaccines for the treatment of type 1 diabetes.

01-07-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

BIOSIM | Accelerating the commercialisation of a disruptive analytical technology which enables the biopharmaceutical industry to manufacture drugs faster, cheaper and with greater regulatory confidence

01-10-2017

-

31-05-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

HoloCyt | A rapid, low-cost, cervical cancer screening platform

01-01-2017

-

30-06-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

tagMDR | Identification of Multidrug Resistance for Chemotherapy Guidance in Cancer Using a Lab-on-a-chip Platform

01-08-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

BGCI | Bacterial Ghost Cancer Immunotherapy - A new standard in tumour therapy based on the bacterial ghost platform technology

01-03-2017

-

31-07-2017

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

OmnImmune | Manufacturing and testing of an allogeneic gamma delta T cell therapy for the treatment of cancer

01-10-2017

-

30-09-2019

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector

BADGER | calScreener® – an innovative device for Bacterial Analysis and Diagnostics through Growth and Energy-release in Real-time

01-07-2016

-

31-12-2016

Show more information
EU-Programme-Call
Horizon 2020
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.3. Treating and managing disease
H2020-EU.3.1.3.0. Cross-cutting call topics
H2020-SMEINST-2-2016-2017
SMEInst-05-2016-2017 Supporting innovative SMEs in the healthcare biotechnology sector
Powered by Chris Decubber BV